中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
21期
3211-3213
,共3页
细胞学检查%基因,h-TERC%基因,myc%子宫肿瘤
細胞學檢查%基因,h-TERC%基因,myc%子宮腫瘤
세포학검사%기인,h-TERC%기인,myc%자궁종류
Cytological examination%Gene,h -TERC%Gene,myc%Uterine neoplasm
目的:探讨阴道脱落细胞检查(TCT)结合人类染色体末端酶基因(h-TERC)和 c-myc 检测在宫颈癌中的价值。方法运用免疫荧光原位杂交技术检测近三年来该院宫颈癌患者500例的宫颈脱落细胞中h-TERC 和 c-myc 的表达,将其检测结果与 TCT 检测结果比较,将上述三种结果的任一阳性检测再进行病理学诊断标准来确定,且以病理诊断为准进行分析。结果在所检测的500例患者中,TCT 异常者132例(26.4%),h-TECR 异常者90例(18.0%),c-myc 异常者80例(16.0%),将270例患者进行阴道宫颈活检技术,在这些病例中,宫颈慢性炎者120例,宫颈病变者150例,其中宫颈上皮瘤变 CINⅠ52例(38.2%),CINⅡ50例(36.4%),CIN Ⅲ30例(18.2%),宫颈癌18例(7.3%)。在所检测的病例中,用原位杂交检测了h-TERC 的含量,其检测结果依次为18.1%、45.4%、52.5%、65.9%、100.0%,同样的 c-myc 的结果依次为21.4%、48.9%、56.7%、59.9%、100.0%,随着 TCT 检测结果的病理程度越高,h-TERC 和 c-myc 的表达越高。结论h-TERC 和 c-myc 检测联合 TCT 更能有效地检测宫颈癌患者的病理程度。
目的:探討陰道脫落細胞檢查(TCT)結閤人類染色體末耑酶基因(h-TERC)和 c-myc 檢測在宮頸癌中的價值。方法運用免疫熒光原位雜交技術檢測近三年來該院宮頸癌患者500例的宮頸脫落細胞中h-TERC 和 c-myc 的錶達,將其檢測結果與 TCT 檢測結果比較,將上述三種結果的任一暘性檢測再進行病理學診斷標準來確定,且以病理診斷為準進行分析。結果在所檢測的500例患者中,TCT 異常者132例(26.4%),h-TECR 異常者90例(18.0%),c-myc 異常者80例(16.0%),將270例患者進行陰道宮頸活檢技術,在這些病例中,宮頸慢性炎者120例,宮頸病變者150例,其中宮頸上皮瘤變 CINⅠ52例(38.2%),CINⅡ50例(36.4%),CIN Ⅲ30例(18.2%),宮頸癌18例(7.3%)。在所檢測的病例中,用原位雜交檢測瞭h-TERC 的含量,其檢測結果依次為18.1%、45.4%、52.5%、65.9%、100.0%,同樣的 c-myc 的結果依次為21.4%、48.9%、56.7%、59.9%、100.0%,隨著 TCT 檢測結果的病理程度越高,h-TERC 和 c-myc 的錶達越高。結論h-TERC 和 c-myc 檢測聯閤 TCT 更能有效地檢測宮頸癌患者的病理程度。
목적:탐토음도탈락세포검사(TCT)결합인류염색체말단매기인(h-TERC)화 c-myc 검측재궁경암중적개치。방법운용면역형광원위잡교기술검측근삼년래해원궁경암환자500례적궁경탈락세포중h-TERC 화 c-myc 적표체,장기검측결과여 TCT 검측결과비교,장상술삼충결과적임일양성검측재진행병이학진단표준래학정,차이병리진단위준진행분석。결과재소검측적500례환자중,TCT 이상자132례(26.4%),h-TECR 이상자90례(18.0%),c-myc 이상자80례(16.0%),장270례환자진행음도궁경활검기술,재저사병례중,궁경만성염자120례,궁경병변자150례,기중궁경상피류변 CINⅠ52례(38.2%),CINⅡ50례(36.4%),CIN Ⅲ30례(18.2%),궁경암18례(7.3%)。재소검측적병례중,용원위잡교검측료h-TERC 적함량,기검측결과의차위18.1%、45.4%、52.5%、65.9%、100.0%,동양적 c-myc 적결과의차위21.4%、48.9%、56.7%、59.9%、100.0%,수착 TCT 검측결과적병리정도월고,h-TERC 화 c-myc 적표체월고。결론h-TERC 화 c-myc 검측연합 TCT 경능유효지검측궁경암환자적병리정도。
Objective To explore the clinical value of Thinprep cytology test (TCT)combined with h -TERC and c -myc in the diagnosis of cervical cancer.Methods hTERC amplification was detected by dual -color interphase fluorescence in situ hybridization (FISH),and the results were compared with TCT and histological examination.Examination the positive which TCT,h -TERC and c -myc by pathological examination.The final diag-nosis was determined by the pathological examination.Results TCT was abnormal in 26.4% of 500 case,18.0%abnormal h -TERC gene,16.0% abnormal c -myc gene.In 270 cases according to the cervical biopsy,the positive rate of chronic inflammation,cervical intraepithelial neoplasia (CIN)Ⅰ,CINⅡ,CINⅢ and cervical cancer:44.4%, 38.2%,36.4%,18.2%,and 7.3% respectively.The positive rates of h -TERC were 18.1%,45.4%,52.5%, 65.9% and 100.0%,respectively.The positive rates of c -myc were 21.4%,48.9%,56.7%,59.9% and 100.0%.With increased pathological grade,the expressions of h -TERC and c -myc were high.Conclusion TCT combined with h -TERC and c -myc can test cervical cancer more effective.